CareLit Fachartikel

Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: A Random…

C Schwarz, S Sutharsan, R Epaud, R Klingsberg, R Fischer, SM Rowe, P Audhya, L Wang, X You, T Ferro · Pneumologie · 2019 · Heft S 01 S 01

Dokument
1194846
CareLit-ID
Jahr
2019
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
C Schwarz, S Sutharsan, R Epaud, R Klingsberg, R Fischer, SM Rowe, P Audhya, L Wang, X You, T Ferro
Ausgabe
Heft S 01 S 01 / 2019
Jahrgang 73
Seiten
–
Erschienen: 2019-03-01 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0039-1678160

Zusammenfassung

Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Who Previously Discontinued Lumacaftor/Ivacaftor Due To Respiratory Adverse Events: A Randomized, Double-Blind, Placebo-Controlled Phase 3b Study

Schlagworte

Ivacaftor Safety Efficacy Tolerability Tezacaftor Cystic Fibrosis Patients Previously Discontinued Lumacaftor Respiratory Pneumologie